Cargando…

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

BACKGROUND: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. METHODS: Eligible participants who received either daclizumab beta or interferon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappos, Ludwig, Cohan, Stanley, Arnold, Douglas L., Robinson, Randy R., Holman, Joan, Fam, Sami, Parks, Becky, Xiao, Shan, Castro-Borrero, Wanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934044/
https://www.ncbi.nlm.nih.gov/pubmed/33737954
http://dx.doi.org/10.1177/1756286420987941
_version_ 1783660747226611712
author Kappos, Ludwig
Cohan, Stanley
Arnold, Douglas L.
Robinson, Randy R.
Holman, Joan
Fam, Sami
Parks, Becky
Xiao, Shan
Castro-Borrero, Wanda
author_facet Kappos, Ludwig
Cohan, Stanley
Arnold, Douglas L.
Robinson, Randy R.
Holman, Joan
Fam, Sami
Parks, Becky
Xiao, Shan
Castro-Borrero, Wanda
author_sort Kappos, Ludwig
collection PubMed
description BACKGROUND: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. METHODS: Eligible participants who received either daclizumab beta or interferon beta-1a in DECIDE received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years in EXTEND, followed by 24 weeks of post-dosing follow-up. Safety and tolerability were evaluated, as were clinical efficacy and magnetic resonance imaging (MRI). EXTEND was terminated ahead of schedule by the sponsors. RESULTS: The total safety population (N = 1203) received at least one dose of daclizumab beta in EXTEND. In the DECIDE and EXTEND combined periods, the median number of doses of daclizumab beta was 53; median time on treatment was 196 weeks. By 24 September 2018, the end of the study, 110/1203 (9%) participants had completed the protocol-specified treatment period and 1101/1203 (92%) had experienced an adverse event (AE). The most commonly reported AEs were MS relapse, nasopharyngitis, and upper respiratory tract infection. Hepatic events (18%), cutaneous events (45%), and infections (62%) were common treatment-related AEs. The incidence of serious AEs was 29%, most commonly MS relapse and infections. The incidence of immune-mediated disorders was 2%; three of seven were encephalitis. Two of six deaths were considered treatment related. In participants who received continuous daclizumab beta throughout DECIDE and EXTEND, the treatment effects on clinical and MRI outcomes were maintained for up to 6 years. CONCLUSION: Results from the combined DECIDE-EXTEND study elucidate outcomes of longer-term treatment with daclizumab beta in the clinical trial setting and underscore the importance of pharmacovigilance with immunomodulatory therapies in the real-world setting.
format Online
Article
Text
id pubmed-7934044
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79340442021-03-17 Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination Kappos, Ludwig Cohan, Stanley Arnold, Douglas L. Robinson, Randy R. Holman, Joan Fam, Sami Parks, Becky Xiao, Shan Castro-Borrero, Wanda Ther Adv Neurol Disord Original Research BACKGROUND: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. METHODS: Eligible participants who received either daclizumab beta or interferon beta-1a in DECIDE received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years in EXTEND, followed by 24 weeks of post-dosing follow-up. Safety and tolerability were evaluated, as were clinical efficacy and magnetic resonance imaging (MRI). EXTEND was terminated ahead of schedule by the sponsors. RESULTS: The total safety population (N = 1203) received at least one dose of daclizumab beta in EXTEND. In the DECIDE and EXTEND combined periods, the median number of doses of daclizumab beta was 53; median time on treatment was 196 weeks. By 24 September 2018, the end of the study, 110/1203 (9%) participants had completed the protocol-specified treatment period and 1101/1203 (92%) had experienced an adverse event (AE). The most commonly reported AEs were MS relapse, nasopharyngitis, and upper respiratory tract infection. Hepatic events (18%), cutaneous events (45%), and infections (62%) were common treatment-related AEs. The incidence of serious AEs was 29%, most commonly MS relapse and infections. The incidence of immune-mediated disorders was 2%; three of seven were encephalitis. Two of six deaths were considered treatment related. In participants who received continuous daclizumab beta throughout DECIDE and EXTEND, the treatment effects on clinical and MRI outcomes were maintained for up to 6 years. CONCLUSION: Results from the combined DECIDE-EXTEND study elucidate outcomes of longer-term treatment with daclizumab beta in the clinical trial setting and underscore the importance of pharmacovigilance with immunomodulatory therapies in the real-world setting. SAGE Publications 2021-02-26 /pmc/articles/PMC7934044/ /pubmed/33737954 http://dx.doi.org/10.1177/1756286420987941 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Kappos, Ludwig
Cohan, Stanley
Arnold, Douglas L.
Robinson, Randy R.
Holman, Joan
Fam, Sami
Parks, Becky
Xiao, Shan
Castro-Borrero, Wanda
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_full Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_fullStr Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_full_unstemmed Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_short Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_sort safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (extend): final results following early termination
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934044/
https://www.ncbi.nlm.nih.gov/pubmed/33737954
http://dx.doi.org/10.1177/1756286420987941
work_keys_str_mv AT kapposludwig safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT cohanstanley safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT arnolddouglasl safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT robinsonrandyr safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT holmanjoan safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT famsami safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT parksbecky safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT xiaoshan safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination
AT castroborrerowanda safetyandefficacyofdaclizumabbetainpatientswithrelapsingmultiplesclerosisina5yearopenlabelstudyextendfinalresultsfollowingearlytermination